Cytotoxic T cells

被引:288
作者
Andersen, Mads Hald
Schrama, David
Straten, Per thor
Becker, Juergen C.
机构
[1] Univ Wurzburg, Klin & Poliklin Dermatol Allergol & Venerol, Sch Med, Dept Dermatol, D-97080 Wurzburg, Germany
[2] Danish Canc Soc, Inst Canc Biol, Tumor Immunol Grp, Copenhagen, Denmark
关键词
D O I
10.1038/sj.jid.5700001
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
The immune system is a complex arrangement of cells and molecules that preserve the integrity of the organism by elimination of all elements judged dangerous. Within the immune system, a humoral and a cellular as well as an innate and an adaptive arm can be differentiated. The key players of adaptive cellular immune responses are T lymphocytes in general and, for the effector function, cytotoxic T lymphocytes (CTLs) in particular. T lymphocytes arise in the bone marrow and migrate to the thymus for maturation. During this process, T cells somatically rearrange gene segments, eventually leading to the expression of a unique antigen-binding molecule, the T-cell receptor (TCR). This receptor allows them to monitor all cells of the body, ready to destroy any cell posing a threat to the organism. Cytotoxicity is exerted directly through the Fas or perforin pathway and/or indirectly by the release of cytokines. Obviously, the activity of such a potent cell is tightly regulated. Indeed, a predominance of stimulatory over inhibitory signals is required for effective immune responses to pathogens, and a predominance of inhibitory over stimulatory signals is required for maintenance of self-tolerance. Still, several situations occur in which an inappropriate CTL response leads to either autoimmune disease or persistence of pathogens.
引用
收藏
页码:32 / 41
页数:10
相关论文
共 81 条
[1]   Phenotypic analysis of antigen-specific T lymphocytes [J].
Altman, JD ;
Moss, PAH ;
Goulder, PJR ;
Barouch, DH ;
McHeyzerWilliams, MG ;
Bell, JI ;
McMichael, AJ ;
Davis, MM .
SCIENCE, 1996, 274 (5284) :94-96
[2]  
Andersen MH, 2001, CANCER RES, V61, P869
[3]  
Andersen MH, 2001, CANCER RES, V61, P5964
[4]   Immunogenicity of constitutively active V599EBRaf [J].
Andersen, MH ;
Fensterle, J ;
Ugurel, S ;
Reker, S ;
Houben, R ;
Guldberg, P ;
Berger, TG ;
Schadendorf, D ;
Trefzer, U ;
Bröcker, EB ;
Straten, PT ;
Rapp, UR ;
Becker, JC .
CANCER RESEARCH, 2004, 64 (15) :5456-5460
[5]   High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993 [J].
Atkins, MB ;
Lotze, MT ;
Dutcher, JP ;
Fisher, RI ;
Weiss, G ;
Margolin, K ;
Abrams, J ;
Sznol, M ;
Parkinson, D ;
Hawkins, M ;
Paradise, C ;
Kunkel, L ;
Rosenberg, SA .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2105-2116
[6]   Accumulation of identical T cells in melanoma and vitiligo-like leukoderma [J].
Becker, JC ;
Guldberg, P ;
Zeuthen, J ;
Bröcker, EB ;
Straten, PT .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1999, 113 (06) :1033-1038
[7]  
Becker JC, 2000, EUR J IMMUNOL, V30, P3699, DOI 10.1002/1521-4141(200012)30:12<3699::AID-IMMU3699>3.0.CO
[8]  
2-2
[9]   Regulatory T cells [J].
Beissert, Stefan ;
Schwarz, Agatha ;
Schwarz, Thomas .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2006, 126 (01) :15-24
[10]   Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele [J].
Bergmann-Leitner, ES ;
Kantor, JA ;
Shupert, WL ;
Schlom, J ;
Abrams, SI .
CELLULAR IMMUNOLOGY, 1998, 187 (02) :103-116